Magdalena Tyrpien, MBA is Co-Founder, President & Chief Executive Officer of Nionyx Bio, a purpose-built kidney AAV company integrating capsid, cassette, and delivery for precision and safety. She brings extensive leadership experience across the gene therapy industry, most notably serving as Chief Business Officer at Forge Biologics, where she helped lead the company’s $620M acquisition by Ajinomoto.

Over the past decade, Ms. Tyrpien has sourced and executed transformative transactions, built and scaled global partnerships, and led capital formation across cell and gene therapy. She has also held senior leadership roles at PTC Therapeutics and Abeona Therapeutics, advancing licensing, acquisitions, and portfolio growth in rare disease. In addition, she is active in industry and community leadership, advising and supporting initiatives that advance innovation, inclusion, and the next generation of biotech founders. She has been recognized by Endpoints News as one of biopharma’s notable leaders. Ms. Tyrpien earned her MBA from the University of Liverpool (UK).